Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.
Irritable bowel syndrome (IBS) is a chronic functional disorder and its development may be linked, directly and indirectly, to intestinal dysbiosis. Here we investigated the interactions between IBS symptoms and the gut microbiome, including the relation to rifaximin (1200 mg daily; 11.2 g per a treatment). We recruited 72 patients, including 31 with IBS-D (diarrhea), 11 with IBS-C (constipation), and 30 with IBS-M (mixed constipation and diarrhea) and 30 healthy controls (HCs). Of them, 68%, 64%, and 53% patients with IBS-D, IBS-C, and IBS-M, respectively, achieved 10-12 week-term improvement after the rifaximin treatment. Stool samples were collected before and after the treatment, and fecal microbiotic profiles were analyzed by deep sequencing of 16S rRNA, while stool metabolic profiles were studied by hydrogen 1-nuclear magnetic resonance ((1)H-NMR) and gas chromatography-mass spectrometry (GC-MS). Of 26 identified phyla, only Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria were consistently found in all samples. Bacteroidetes was predominant in fecal samples from HCs and IBS-D and IBS-M subjects, whereas Firmicutes was predominant in samples from IBS-C subjects. Species richness, but not community diversity, differentiated all IBS patients from HCs. Metabolic fingerprinting, using NMR spectra, distinguished HCs from all IBS patients. Thirteen metabolites identified by GC-MS differed HCs and IBS patients. However, neither metagenomics nor metabolomics analyses identified significant differences between patients with and without improvement after treatment.
a Department of Gastroenterology, Hepatology and Clinical Oncology , Medical Center for Postgraduate Education , Warsaw , Poland.
Natalia
N
Zeber-Lubecka
a Department of Gastroenterology, Hepatology and Clinical Oncology , Medical Center for Postgraduate Education , Warsaw , Poland.
Maria
M
Kulecka
a Department of Gastroenterology, Hepatology and Clinical Oncology , Medical Center for Postgraduate Education , Warsaw , Poland.
Filip
F
Ambrozkiewicz
a Department of Gastroenterology, Hepatology and Clinical Oncology , Medical Center for Postgraduate Education , Warsaw , Poland.
Agnieszka
A
Paziewska
b Department of Genetics , Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Warsaw , Poland.
Krzysztof
K
Goryca
b Department of Genetics , Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Warsaw , Poland.
Jakub
J
Karczmarski
c Institute of Radioelectronics, Warsaw University of Technology , Warsaw , Poland.
Tymon
T
Rubel
d Department of Bioorganic Chemistry Wroclaw University of Technology , Wroclaw , Poland.
Wojciech
W
Wojtowicz
d Department of Bioorganic Chemistry Wroclaw University of Technology , Wroclaw , Poland.
Piotr
P
Mlynarz
e Institute of Bioorganic Chemistry Polish Academy of Sciences , Poznań , Poland.
Lukasz
L
Marczak
a Department of Gastroenterology, Hepatology and Clinical Oncology , Medical Center for Postgraduate Education , Warsaw , Poland.
Roman
R
Tomecki
b Department of Genetics , Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Warsaw , Poland.
Michal
M
Mikula
a Department of Gastroenterology, Hepatology and Clinical Oncology , Medical Center for Postgraduate Education , Warsaw , Poland.|b Department of Genetics , Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Warsaw , Poland.
Jerzy
J
Ostrowski
D000328:Adult; D001419:Bacteria / Q000145:classification / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification*; D005243:Feces / Q000382:microbiology*; D005260:Female; D000069196:Gastrointestinal Microbiome / Q000187:drug effects*; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000382:microbiology; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D008297:Male; D055442:Metabolome / Q000187:drug effects*; D008875:Middle Aged; D012294:Rifamycins / Q000008:administration & dosage*; D000078262:Rifaximin; D013997:Time Factors; D055815:Young Adult
D012294:Rifamycins; D000078262:Rifaximin
16s rRNA sequencing; irritable bowel syndrome; metabolomics; metagenomics; rifaximin
Aliment Pharmacol Ther. 2014 May;39(10):1161-8
24697851
Expert Rev Anti Infect Ther. 2010 Apr;8(4):435-54
20377338
FEMS Immunol Med Microbiol. 2005 Aug 1;45(2):183-9
15939578
PLoS One. 2013;8(4):e60042
23565181
World J Gastroenterol. 2014 Jul 21;20(27):8807-20
25083055
J Med Microbiol. 1987 Feb;23(1):29-32
3820268
Bioinformatics. 2014 Nov 1;30(21):3123-4
25061070
Clin Exp Gastroenterol. 2015 Dec 04;8:309-25
26673000
Gastroenterology. 2002 Dec;123(6):2108-31
12454866
Neurogastroenterol Motil. 2012 Jun;24(6):521-30, e248
22339879
PLoS One. 2016 Feb 26;11(2):e0150306
26918330
Nature. 2011 May 12;473(7346):174-80
21508958
BMC Gastroenterol. 2009 Dec 17;9:95
20015409
Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):111-6
19499846
Environ Microbiol. 2007 Sep;9(9):2125-36
17686012
Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:37-49
26618924
Appl Environ Microbiol. 2014 Dec;80(24):7583-91
25261520
Neurogastroenterol Motil. 2010 May;22(5):512-9, e114-5
19903265
Aliment Pharmacol Ther. 2012 Dec;36(11-12):1084-93
23066911
Am J Gastroenterol. 2014 Oct;109(10):1547-61; quiz 1546, 1562
25070051
Aliment Pharmacol Ther. 1997 Dec;11(6):1067-72
9663831
Am J Gastroenterol. 2012 Nov;107(11):1740-51
22986438
Aliment Pharmacol Ther. 2005 Jul 1;22(1):31-5
15963077
Aliment Pharmacol Ther. 2012 Apr;35(7):828-38
22315951
Eur Rev Med Pharmacol Sci. 2013 May;17(10):1314-20
23740443
FEMS Immunol Med Microbiol. 2005 Feb 1;43(2):213-22
15747442
Gut. 2012 Jul;61(7):997-1006
22180058
Ann Intern Med. 2006 Oct 17;145(8):557-63
17043337
World J Gastroenterol. 2009 Dec 28;15(48):6068-74
20027679
Gastroenterology. 2006 Apr;130(5):1377-90
16678553
Bioinformatics. 2009 Aug 15;25(16):2078-9
19505943
World J Gastrointest Pharmacol Ther. 2013 Nov 6;4(4):97-107
24199025
J Med Microbiol. 2011 Feb;60(Pt 2):236-45
20947663
World J Gastroenterol. 2004 Jun 15;10(12):1802-5
15188510
Am J Gastroenterol. 2005 Feb;100(2):373-82
15667495
Ann Gastroenterol. 2015 Jan-Mar;28(1):87-93
25609236
Nat Rev Gastroenterol Hepatol. 2012 Oct;9(10):599-608
22907164
NMR Biomed. 2009 Apr;22(3):342-8
19006102
Minerva Gastroenterol Dietol. 2006 Mar;52(1):89-95
16554709
Gastroenterology. 2007 Jul;133(1):24-33
17631127
Dig Dis Sci. 2008 Jan;53(1):169-74
17520365
Microbiome. 2015 Jun 22;3:26
26120470
Dig Dis Sci. 2010 Feb;55(2):392-7
19693670
World J Gastroenterol. 2009 Jun 7;15(21):2628-31
19496193
Gastroenterology. 2009 Jan;136(1):65-80
19026645
Arch Med Sci. 2010 Mar 1;6(1):49-55
22371720
J Hepatol. 2013 May;58(5):949-55
23333527
Gastroenterology. 2009 May;136(6):1979-88
19457422
World J Gastroenterol. 2014 Jul 21;20(27):8796-806
25083054
Science. 2005 Jun 10;308(5728):1635-8
15831718
Am J Gastroenterol. 2006 Feb;101(2):326-33
16454838
PLoS One. 2013;8(3):e58204
23516449
Am J Gastroenterol. 2012 Jan;107(1):28-35; quiz 36
22045120
Gastroenterology. 2014 Feb;146(2):484-96.e4
24161699
World J Gastroenterol. 2014 Sep 14;20(34):12144-60
25232249
World J Gastroenterol. 2014 Jul 21;20(27):8886-97
25083061
Aliment Pharmacol Ther. 2008 Jan 15;27(2):120-45
17922802
Iran J Pediatr. 2012 Sep;22(3):364-8
23400266
Nat Biotechnol. 2013 Sep;31(9):814-21
23975157
World J Gastroenterol. 2014 Jul 21;20(27):8821-36
25083056
Ther Adv Chronic Dis. 2013 Mar;4(2):71-5
23556126
World J Gastroenterol. 2014 Jan 7;20(1):163-74
24415869
Aliment Pharmacol Ther. 2007 Apr 1;25(7):781-6
17373916
Clin Exp Gastroenterol. 2015 Jun 08;8:159-67
26089696
World J Gastroenterol. 2014 Jul 21;20(27):8837-45
25083057
World J Gastroenterol. 2009 Dec 21;15(47):5936-45
20014457
Br J Nutr. 2014 Feb;111(3):387-402
23931069
World J Gastroenterol. 2014 Jul 21;20(27):8859-66
25083059
Gut Pathog. 2010 Dec 09;2(1):19
21143915
Clin Med Insights Gastroenterol. 2012 Jun 25;5:31-41
24833932
Sci Rep. 2015 Feb 17;5:8508
25687743
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
19801464
Trends Genet. 2013 Jan;29(1):51-8
23140990
Aliment Pharmacol Ther. 2007 Jun 1;25(11):1271-81
17509095
Gastroenterology. 2006 Apr;130(5):1480-91
16678561
Gastroenterology. 2011 Nov;141(5):1782-91
21741921
Environ Microbiol Rep. 2012 Apr;4(2):242-7
23757279
Behav Res Methods. 2007 May;39(2):175-91
17695343
Z Gastroenterol. 2009 Jul;47(7):653-8
19606407
J Proteome Res. 2011 Sep 2;10(9):4208-18
21761941
Aliment Pharmacol Ther. 2000 Aug;14(8):1001-8
10930893
N Engl J Med. 2011 Jan 6;364(1):22-32
21208106
J Med Microbiol. 2011 Jun;60(Pt 6):817-27
21330412